Author Affiliations: Department of Orthopaedics, Southwest Hospital, Chongqing, China (firstname.lastname@example.org).
To the Editor: The study presented by Dr Otten and colleagues assessed factors associated with treatment response to etanercept in patients with juvenile idiopathic arthritis (JIA).1 They found that approximately one-third of the patients with JIA achieved an excellent response, which was associated with low baseline disability scores, low numbers of disease-modifying antirheumatic drugs used before initiating etanercept, and younger age at onset of JIA. One-third achieved a poor response, which was associated with systemic JIA and female sex.1
Pang H, Wu X, Xu J. Response to Etanercept in Juvenile Idiopathic Arthritis. JAMA. 2012;307(11):1140-1141. doi:10.1001/jama.2012.328